Stacy Loeb, MD, MSc, discusses a study evaluating levels of at microplastics and nanoplastics in prostate cancer tissue. Loeb explained that her interest in this work was sparked by a study published ...
The ANDROMEDA trial compares alpha-emitting 225Ac-PSMA-617 and beta-emitting 177Lu-PSMA-617 with SBRT for recurrent oligometastatic prostate cancer. The trial builds on the LUNAR trial, which showed ...
Aleece Fosnight, MSPAS, PA-C, highlights pattern recognition as a cornerstone of diagnosis, encouraging clinicians to closely examine how urinary symptoms fluctuate across the menstrual cycle. In this ...
FDA approved Gozellix for prostate cancer imaging and expanded 177Lu-PSMA-617's label for mCRPC treatment. 64Cu-SAR-bisPSMA demonstrated efficacy in detecting recurrent prostate cancer in the COBRA ...
DARE to PLAY is a topical sildenafil cream enhancing female arousal, available in select states as a compounded product while awaiting FDA approval. Clinical trials showed improved arousal sensation ...
Individualized hormone therapy duration for prostate cancer can reduce unnecessary treatment and side effects, based on cancer risk. Meta-analysis of 10,266 men showed diminishing benefits of ADT ...
ORIC-944 demonstrated significant anti-tumor activity and tolerability in combination with ARPIs in mCRPC patients. The phase 1b trial showed notable PSA and ctDNA reductions across all ORIC-944 dose ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Technological advancements in sacral neuromodulation include MRI-conditional devices, rechargeable systems, and extended battery lifespans, enhancing patient eligibility and reducing procedural ...
Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UUI patients. The SANS-UUI trial showed 84.2% of patients achieved at least a 50 ...
“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” says Dean Elterman, MD. “We're now entering an era of new types of technologies to treat BPH in a ...
UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results